Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer

Cancer Discovery

Volumn 5, Issue 5, 2015, Pages 521-533

  Zhang, Mei ^a   Tsimelzon, Anna ^b   Chang, Chi Hsuan ^b   Fan, Cheng ^c   Wolff, Andrew ^d   Perou, Charles M ^c,e   Hilsenbeck, Susan G ^b   Rosen, Jeffrey M ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d CARNEGIE MELLON UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD24 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; INTERLEUKIN 6; PROTEIN P53; STROMAL CELL DERIVED FACTOR 1; TRP53 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; WNT2 PROTEIN; WNT9A PROTEIN; MEMBRANE ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BREAST CANCER; CARCINOGENICITY; CELL HETEROGENEITY; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; IMMUNOHISTOCHEMISTRY; MESENCHYMOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL NICHE; TREATMENT RESPONSE; TRP53 GENE; TUMOR GENE; TUMOR GROWTH; ANIMAL; BREAST TUMOR; CANCER STEM CELL; CELL CYCLE; CELL SELF-RENEWAL; CELL TRANSFORMATION; COCULTURE; DEFICIENCY; DISEASE MODEL; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOPHENOTYPING; KNOCKOUT MOUSE; METABOLISM; NUDE MOUSE; PATHOLOGY;

ANIMALS; ANTIGENS, SURFACE; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL CYCLE; CELL SELF RENEWAL; CELL TRANSFORMATION, NEOPLASTIC; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPHENOTYPING; MICE; MICE, KNOCKOUT; MICE, NUDE; NEOPLASTIC STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84932089510     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-1101     Document Type: Article

References (49)

1. Rosen JM, Roarty K. Paracrine signaling in mammary gland development: what can we learn about intratumoral heterogeneity ? Breast Cancer Res 2014; 16: 202.
2. Forster N, Saladi SV, van Bragt M, Sfondouris ME, Jones FE, Li Z, et al. Basal cell signaling by p63 controls luminal progenitor function and lactation via NRG1. Dev Cell 2014; 28: 147-60.
3. Katona TM, Jones TD, Wang M, Eble JN, Billings SD, Cheng L. Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma. Am J Surg Pathol 2007; 31: 1029–37.
4. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006; 38: 468-73.
5. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
6. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell 2012; 149: 994-1007.
7. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339–44.
8. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013; 8: 277-302.
9. Kreso A, O’Brien CA, van Galen P, Gan OI, Notta F, Brown AM, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013; 339: 543-8.
10. Campbell PJ, Pleasance ED, Stephens PJ, Dicks E, Rance R, Goodhead I, et al. Subclonal phylogenetic structures in cancer revealed by ultradeep sequencing. Proc Natl Acad Sci U S A 2008; 105: 13081-6.
11. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472: 90-4.
12. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883–92.
13. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007; 23: 675-99.
14. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253–70.
15. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-9.
16. Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG, et al. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med 2010; 2: 55ra79.
17. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiationresistant tumor-initiating cells. Proc Natl Acad Sci U S A 2010; 107: 3522-7.
18. Yang G, Quan Y, Wang W, Fu Q, Wu J, Mei T, et al. Dynamic equi librium between cancer stem cells and non-stem cancer cells in human SW620 and MCF-7 cancer cell populations. Br J Cancer 2012; 106: 1512–9.
19. Li L, Clevers H. Coexistence of quiescent and active adult stem cells in mammals. Science 2010; 327: 542-5.
20. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008; 68: 4674-82.
21. Morrison SJ, Spradling AC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 2008; 132: 598-611.
22. Li J, Jiang T, Mao JH, Balmain A, Peterson L, Harris C, et al. Genomic segmental polymorphisms in inbred mouse strains. Nat Genet 2004; 36: 952-4.
23. Cai WW, Mao JH, Chow CW, Damani S, Balmain A, Bradley A. Genome-wide detection of chromosomal imbalances in tumors using BAC microarrays. Nat Biotechnol 2002; 20: 393-6.
24. Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, et al. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics 2011; 4: 3.
25. Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol 2013; 14: R125.
26. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007; 8: R76.
27. Zeng YA, Nusse R. Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture . Cell Stem Cell 2010; 6: 568–77.
28. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011; 71: 614–24.
29. Gatti M, Pattarozzi A, Bajetto A, Wurth R, Daga A, Fiaschi P, et al. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity . Toxicology 2013; 314: 209-20.
30. Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, et al. Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity . Cell Rep 2014; 6: 514-27.
31. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma . Science 2014; 344: 1396-401.
32. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features . Proc Natl Acad Sci U S A 2009; 106: 13820-5.
33. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma . Cancer Cell 2010; 17: 362-75.
34. Park SY, Gonen M, Kim HJ, Michor F, Polyak K . Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype . J Clin Invest 2010; 120: 636-44.
35. Dale TC, Weber-Hall SJ, Smith K, Huguet EL, Jayatilake H, Gusterson BA, et al. Compartment switching of WNT-2 expression in human breast tumors . Cancer Res 1996; 56: 4320-3.
36. Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 2014; 346: 1248012.
37. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis . Cancer Cell 2004; 6: 459-69.
38. Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ . Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111: 187-96.
39. Machelon V, Gaudin F, Camilleri-Broet S, Nasreddine S, Bouchet- Delbos L, Pujade-Lauraine E, et al. CXCL12 expression by healthy and malignant ovarian epithelial cells . BMC Cancer 2011; 11: 97.
40. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland . J Clin Invest 2007; 117: 3988-4002.
41. Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2 + breast cancer by expanding the cancer stem cell population . Mol Cell 2012; 47: 570-84.
42. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas . J Clin Invest 2007; 117: 3846-56.
43. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells . Cell 2002; 111: 241-50.
44. Akunuru S, James Zhai Q, Zheng Y . Non–small cell lung cancer stem/ progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity . Cell Death Dis 2012; 3: e352.
45. Rubio CA . Further studies on the arrest of cell proliferation in tumor cells at the invading front of colonic adenocarcinoma . J Gastroenterol Hepatol 2007; 22: 1877-81.
46. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrinetherapy- resistant ESR1 variants revealed by genomic characterization of breast-cancer–derived xenografts . Cell Rep 2013; 4: 1116-30.
47. Cleary AS, Leonard TL, Gestl SA, Gunther EJ . Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers . Nature 2014; 508: 113-7.
48. Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K . Non-cell-autonomous driving of tumour growth supports subclonal heterogeneity . Nature 2014; 514: 54-8.
49. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing . Nature 2014; 512: 155-60.